nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—Flank pain—Telbivudine—hepatitis B	0.0231	0.0351	CcSEcCtD
Rasagiline—Muscle atrophy—Lamivudine—hepatitis B	0.0223	0.0339	CcSEcCtD
Rasagiline—MAOB—Alpha-synuclein signaling—UBE2L3—hepatitis B	0.02	0.0584	CbGpPWpGaD
Rasagiline—Cough increased—Adefovir Dipivoxil—hepatitis B	0.0121	0.0184	CcSEcCtD
Rasagiline—Neck pain—Telbivudine—hepatitis B	0.00942	0.0143	CcSEcCtD
Rasagiline—Musculoskeletal pain—Telbivudine—hepatitis B	0.00942	0.0143	CcSEcCtD
Rasagiline—CYP1A2—Estrogen Receptor Pathway—NR0B2—hepatitis B	0.00788	0.023	CbGpPWpGaD
Rasagiline—Liver function test abnormal—Adefovir Dipivoxil—hepatitis B	0.00741	0.0113	CcSEcCtD
Rasagiline—Migraine—Telbivudine—hepatitis B	0.00665	0.0101	CcSEcCtD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—FASLG—hepatitis B	0.00661	0.0193	CbGpPWpGaD
Rasagiline—Upper respiratory tract infection—Entecavir—hepatitis B	0.00661	0.01	CcSEcCtD
Rasagiline—Weight decreased—Adefovir Dipivoxil—hepatitis B	0.00628	0.00954	CcSEcCtD
Rasagiline—CYP1A2—Aflatoxin activation and detoxification—GGT2—hepatitis B	0.00626	0.0183	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—CDKN2A—hepatitis B	0.00618	0.0181	CbGpPWpGaD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—FASLG—hepatitis B	0.00613	0.0179	CbGpPWpGaD
Rasagiline—Haematuria—Entecavir—hepatitis B	0.00605	0.00919	CcSEcCtD
Rasagiline—Jaundice—Adefovir Dipivoxil—hepatitis B	0.00603	0.00917	CcSEcCtD
Rasagiline—Muscular weakness—Telbivudine—hepatitis B	0.00596	0.00906	CcSEcCtD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—FAS—hepatitis B	0.00591	0.0173	CbGpPWpGaD
Rasagiline—Haematuria—Adefovir Dipivoxil—hepatitis B	0.0059	0.00897	CcSEcCtD
Rasagiline—Influenza—Telbivudine—hepatitis B	0.00584	0.00888	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—APOBEC3G—hepatitis B	0.00577	0.0169	CbGpPWpGaD
Rasagiline—Drug interaction—Lamivudine—hepatitis B	0.00566	0.0086	CcSEcCtD
Rasagiline—Oedema peripheral—Entecavir—hepatitis B	0.00561	0.00852	CcSEcCtD
Rasagiline—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.00548	0.00834	CcSEcCtD
Rasagiline—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.00546	0.0083	CcSEcCtD
Rasagiline—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.00544	0.00828	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Telbivudine—hepatitis B	0.00543	0.00825	CcSEcCtD
Rasagiline—Musculoskeletal pain—Lamivudine—hepatitis B	0.00531	0.00807	CcSEcCtD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—CYP2A6—hepatitis B	0.00529	0.0155	CbGpPWpGaD
Rasagiline—Immune system disorder—Entecavir—hepatitis B	0.00514	0.00782	CcSEcCtD
Rasagiline—Neuropathy peripheral—Telbivudine—hepatitis B	0.00511	0.00776	CcSEcCtD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—FASLG—hepatitis B	0.00505	0.0148	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—CDKN1A—hepatitis B	0.00505	0.0148	CbGpPWpGaD
Rasagiline—Alopecia—Entecavir—hepatitis B	0.00503	0.00765	CcSEcCtD
Rasagiline—Mental disorder—Entecavir—hepatitis B	0.00499	0.00758	CcSEcCtD
Rasagiline—Malnutrition—Entecavir—hepatitis B	0.00496	0.00753	CcSEcCtD
Rasagiline—Photophobia—Lamivudine—hepatitis B	0.00493	0.00749	CcSEcCtD
Rasagiline—Neuropathy—Lamivudine—hepatitis B	0.00493	0.00749	CcSEcCtD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—FAS—hepatitis B	0.00487	0.0142	CbGpPWpGaD
Rasagiline—Malnutrition—Adefovir Dipivoxil—hepatitis B	0.00483	0.00735	CcSEcCtD
Rasagiline—BCL2—Inflammasomes—NFKB1—hepatitis B	0.00481	0.0141	CbGpPWpGaD
Rasagiline—Flatulence—Adefovir Dipivoxil—hepatitis B	0.00476	0.00724	CcSEcCtD
Rasagiline—Urine output increased—Lamivudine—hepatitis B	0.00474	0.00721	CcSEcCtD
Rasagiline—Mouth ulceration—Lamivudine—hepatitis B	0.00474	0.00721	CcSEcCtD
Rasagiline—Gynaecomastia—Lamivudine—hepatitis B	0.0047	0.00714	CcSEcCtD
Rasagiline—Back pain—Adefovir Dipivoxil—hepatitis B	0.00468	0.00711	CcSEcCtD
Rasagiline—Hypoaesthesia—Telbivudine—hepatitis B	0.00465	0.00707	CcSEcCtD
Rasagiline—MAOB—Biological oxidations—GGT2—hepatitis B	0.00464	0.0136	CbGpPWpGaD
Rasagiline—Connective tissue disorder—Telbivudine—hepatitis B	0.00459	0.00699	CcSEcCtD
Rasagiline—Anaemia—Adefovir Dipivoxil—hepatitis B	0.00447	0.00679	CcSEcCtD
Rasagiline—Leukopenia—Entecavir—hepatitis B	0.00444	0.00674	CcSEcCtD
Rasagiline—Phlebitis—Lamivudine—hepatitis B	0.00442	0.00672	CcSEcCtD
Rasagiline—CYP1A2—Fatty Acid Omega Oxidation—CYP2A6—hepatitis B	0.00435	0.0127	CbGpPWpGaD
Rasagiline—Polyuria—Lamivudine—hepatitis B	0.00434	0.00659	CcSEcCtD
Rasagiline—BCL2—Estrogen signaling pathway—NFKB1—hepatitis B	0.00431	0.0126	CbGpPWpGaD
Rasagiline—Gastroenteritis—Lamivudine—hepatitis B	0.0043	0.00653	CcSEcCtD
Rasagiline—Deafness—Lamivudine—hepatitis B	0.00426	0.00647	CcSEcCtD
Rasagiline—Cough—Adefovir Dipivoxil—hepatitis B	0.00422	0.00641	CcSEcCtD
Rasagiline—Mediastinal disorder—Telbivudine—hepatitis B	0.00421	0.00641	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.00419	0.00637	CcSEcCtD
Rasagiline—Injury—Lamivudine—hepatitis B	0.00414	0.0063	CcSEcCtD
Rasagiline—Chest pain—Adefovir Dipivoxil—hepatitis B	0.00412	0.00626	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.00409	0.00621	CcSEcCtD
Rasagiline—Malnutrition—Telbivudine—hepatitis B	0.00407	0.00619	CcSEcCtD
Rasagiline—Infection—Entecavir—hepatitis B	0.00402	0.00611	CcSEcCtD
Rasagiline—Dysgeusia—Telbivudine—hepatitis B	0.00399	0.00606	CcSEcCtD
Rasagiline—Nervous system disorder—Entecavir—hepatitis B	0.00397	0.00603	CcSEcCtD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—FASLG—hepatitis B	0.00396	0.0116	CbGpPWpGaD
Rasagiline—Back pain—Telbivudine—hepatitis B	0.00394	0.00599	CcSEcCtD
Rasagiline—Skin disorder—Entecavir—hepatitis B	0.00393	0.00597	CcSEcCtD
Rasagiline—Muscle spasms—Telbivudine—hepatitis B	0.00391	0.00595	CcSEcCtD
Rasagiline—BCL2—Overview of nanoparticle effects—TNF—hepatitis B	0.0039	0.0114	CbGpPWpGaD
Rasagiline—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.00387	0.00588	CcSEcCtD
Rasagiline—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.00383	0.00583	CcSEcCtD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—FAS—hepatitis B	0.00382	0.0112	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Telbivudine—hepatitis B	0.00378	0.00574	CcSEcCtD
Rasagiline—Anorexia—Adefovir Dipivoxil—hepatitis B	0.00376	0.00572	CcSEcCtD
Rasagiline—Affect lability—Lamivudine—hepatitis B	0.00375	0.0057	CcSEcCtD
Rasagiline—Migraine—Lamivudine—hepatitis B	0.00375	0.0057	CcSEcCtD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—IL2—hepatitis B	0.00372	0.0109	CbGpPWpGaD
Rasagiline—Malaise—Telbivudine—hepatitis B	0.00367	0.00558	CcSEcCtD
Rasagiline—Insomnia—Entecavir—hepatitis B	0.00366	0.00556	CcSEcCtD
Rasagiline—CYP1A2—Xenobiotics—CYP2A6—hepatitis B	0.00364	0.0106	CbGpPWpGaD
Rasagiline—Mood swings—Lamivudine—hepatitis B	0.00361	0.00549	CcSEcCtD
Rasagiline—Somnolence—Entecavir—hepatitis B	0.0036	0.00547	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.00359	0.00546	CcSEcCtD
Rasagiline—Dyspepsia—Entecavir—hepatitis B	0.00356	0.00541	CcSEcCtD
Rasagiline—Cough—Telbivudine—hepatitis B	0.00355	0.0054	CcSEcCtD
Rasagiline—Liver function test abnormal—Lamivudine—hepatitis B	0.00352	0.00535	CcSEcCtD
Rasagiline—CYP1A2—Tamoxifen metabolism—CYP2A6—hepatitis B	0.0035	0.0102	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Entecavir—hepatitis B	0.00349	0.00531	CcSEcCtD
Rasagiline—Dyspepsia—Adefovir Dipivoxil—hepatitis B	0.00347	0.00528	CcSEcCtD
Rasagiline—Arthralgia—Telbivudine—hepatitis B	0.00347	0.00527	CcSEcCtD
Rasagiline—Chest pain—Telbivudine—hepatitis B	0.00347	0.00527	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.00344	0.00523	CcSEcCtD
Rasagiline—BCL2—TP53 Network—TP53—hepatitis B	0.00344	0.0101	CbGpPWpGaD
Rasagiline—Decreased appetite—Adefovir Dipivoxil—hepatitis B	0.00343	0.00521	CcSEcCtD
Rasagiline—Discomfort—Telbivudine—hepatitis B	0.00342	0.0052	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.00341	0.00518	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IFNB1—hepatitis B	0.00338	0.00988	CbGpPWpGaD
Rasagiline—Muscular weakness—Lamivudine—hepatitis B	0.00336	0.00511	CcSEcCtD
Rasagiline—Gastrointestinal pain—Entecavir—hepatitis B	0.00331	0.00503	CcSEcCtD
Rasagiline—BCL2—EPO signaling pathway—NFKB1—hepatitis B	0.00331	0.00966	CbGpPWpGaD
Rasagiline—Dysphagia—Lamivudine—hepatitis B	0.00329	0.005	CcSEcCtD
Rasagiline—Influenza—Lamivudine—hepatitis B	0.00329	0.005	CcSEcCtD
Rasagiline—Nervous system disorder—Telbivudine—hepatitis B	0.00326	0.00495	CcSEcCtD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—hepatitis B	0.00325	0.0095	CbGpPWpGaD
Rasagiline—Skin disorder—Telbivudine—hepatitis B	0.00323	0.00491	CcSEcCtD
Rasagiline—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.00323	0.0049	CcSEcCtD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—NFKB1—hepatitis B	0.00323	0.00943	CbGpPWpGaD
Rasagiline—Abdominal pain—Entecavir—hepatitis B	0.0032	0.00486	CcSEcCtD
Rasagiline—Body temperature increased—Entecavir—hepatitis B	0.0032	0.00486	CcSEcCtD
Rasagiline—BCL2—ATF-2 transcription factor network—NOS2—hepatitis B	0.00317	0.00928	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—IL6—hepatitis B	0.00315	0.0092	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—IL2—hepatitis B	0.00314	0.00919	CbGpPWpGaD
Rasagiline—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.00312	0.00474	CcSEcCtD
Rasagiline—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.00312	0.00474	CcSEcCtD
Rasagiline—Dysuria—Lamivudine—hepatitis B	0.00308	0.00468	CcSEcCtD
Rasagiline—Pollakiuria—Lamivudine—hepatitis B	0.00304	0.00462	CcSEcCtD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TNF—hepatitis B	0.00304	0.00887	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.00303	0.0046	CcSEcCtD
Rasagiline—Insomnia—Telbivudine—hepatitis B	0.003	0.00457	CcSEcCtD
Rasagiline—Paraesthesia—Telbivudine—hepatitis B	0.00298	0.00453	CcSEcCtD
Rasagiline—CYP1A2—Aflatoxin activation and detoxification—GGT1—hepatitis B	0.00296	0.00865	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—IL2—hepatitis B	0.00295	0.00863	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—NFKB1—hepatitis B	0.00294	0.0086	CbGpPWpGaD
Rasagiline—Depression—Lamivudine—hepatitis B	0.00293	0.00445	CcSEcCtD
Rasagiline—Dyspepsia—Telbivudine—hepatitis B	0.00292	0.00445	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—IL18—hepatitis B	0.00291	0.00851	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—FASLG—hepatitis B	0.0029	0.00848	CbGpPWpGaD
Rasagiline—Asthenia—Entecavir—hepatitis B	0.0029	0.00441	CcSEcCtD
Rasagiline—Neuropathy peripheral—Lamivudine—hepatitis B	0.00288	0.00437	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Telbivudine—hepatitis B	0.00287	0.00436	CcSEcCtD
Rasagiline—Stomatitis—Lamivudine—hepatitis B	0.00286	0.00435	CcSEcCtD
Rasagiline—Jaundice—Lamivudine—hepatitis B	0.00286	0.00435	CcSEcCtD
Rasagiline—BCL2—IL-2 Signaling Pathway—IL2—hepatitis B	0.00284	0.0083	CbGpPWpGaD
Rasagiline—Asthenia—Adefovir Dipivoxil—hepatitis B	0.00283	0.0043	CcSEcCtD
Rasagiline—Sweating—Lamivudine—hepatitis B	0.00281	0.00428	CcSEcCtD
Rasagiline—MAOB—Biological oxidations—CYP2A6—hepatitis B	0.00281	0.00821	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—FAS—hepatitis B	0.0028	0.00818	CbGpPWpGaD
Rasagiline—Pruritus—Adefovir Dipivoxil—hepatitis B	0.00279	0.00424	CcSEcCtD
Rasagiline—Epistaxis—Lamivudine—hepatitis B	0.00277	0.00421	CcSEcCtD
Rasagiline—Diarrhoea—Entecavir—hepatitis B	0.00277	0.00421	CcSEcCtD
Rasagiline—BCL2—Activation of BH3-only proteins—TP53—hepatitis B	0.00276	0.00807	CbGpPWpGaD
Rasagiline—Feeling abnormal—Telbivudine—hepatitis B	0.00274	0.00416	CcSEcCtD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—FASLG—hepatitis B	0.00272	0.00795	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Telbivudine—hepatitis B	0.00272	0.00413	CcSEcCtD
Rasagiline—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.0027	0.0041	CcSEcCtD
Rasagiline—Dizziness—Entecavir—hepatitis B	0.00267	0.00407	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—HNF4A—hepatitis B	0.00267	0.0078	CbGpPWpGaD
Rasagiline—Rhinitis—Lamivudine—hepatitis B	0.00264	0.00402	CcSEcCtD
Rasagiline—Abdominal pain—Telbivudine—hepatitis B	0.00263	0.00399	CcSEcCtD
Rasagiline—Body temperature increased—Telbivudine—hepatitis B	0.00263	0.00399	CcSEcCtD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—FAS—hepatitis B	0.00262	0.00767	CbGpPWpGaD
Rasagiline—Hypoaesthesia—Lamivudine—hepatitis B	0.00262	0.00399	CcSEcCtD
Rasagiline—BCL2—IL2-mediated signaling events—IFNG—hepatitis B	0.00261	0.00764	CbGpPWpGaD
Rasagiline—Connective tissue disorder—Lamivudine—hepatitis B	0.00259	0.00394	CcSEcCtD
Rasagiline—BCL2—Integrated Cancer Pathway—CDKN1A—hepatitis B	0.00258	0.00754	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—PTEN—hepatitis B	0.00257	0.00752	CbGpPWpGaD
Rasagiline—Vomiting—Entecavir—hepatitis B	0.00257	0.00391	CcSEcCtD
Rasagiline—Rash—Entecavir—hepatitis B	0.00255	0.00388	CcSEcCtD
Rasagiline—Dermatitis—Entecavir—hepatitis B	0.00255	0.00387	CcSEcCtD
Rasagiline—Headache—Entecavir—hepatitis B	0.00253	0.00385	CcSEcCtD
Rasagiline—Vomiting—Adefovir Dipivoxil—hepatitis B	0.00251	0.00381	CcSEcCtD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—hepatitis B	0.00251	0.00733	CbGpPWpGaD
Rasagiline—Rash—Adefovir Dipivoxil—hepatitis B	0.00249	0.00378	CcSEcCtD
Rasagiline—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.00249	0.00378	CcSEcCtD
Rasagiline—Headache—Adefovir Dipivoxil—hepatitis B	0.00247	0.00376	CcSEcCtD
Rasagiline—BCL2—ATF-2 transcription factor network—IFNG—hepatitis B	0.00244	0.00712	CbGpPWpGaD
Rasagiline—Nausea—Entecavir—hepatitis B	0.0024	0.00365	CcSEcCtD
Rasagiline—BCL2—Ceramide signaling pathway—NFKB1—hepatitis B	0.00239	0.00698	CbGpPWpGaD
Rasagiline—Asthenia—Telbivudine—hepatitis B	0.00238	0.00362	CcSEcCtD
Rasagiline—Immune system disorder—Lamivudine—hepatitis B	0.00238	0.00362	CcSEcCtD
Rasagiline—Mediastinal disorder—Lamivudine—hepatitis B	0.00237	0.00361	CcSEcCtD
Rasagiline—Chills—Lamivudine—hepatitis B	0.00236	0.00359	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—FASLG—hepatitis B	0.00236	0.00689	CbGpPWpGaD
Rasagiline—Pruritus—Telbivudine—hepatitis B	0.00235	0.00357	CcSEcCtD
Rasagiline—Nausea—Adefovir Dipivoxil—hepatitis B	0.00234	0.00356	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—TLR4—hepatitis B	0.00234	0.00684	CbGpPWpGaD
Rasagiline—Alopecia—Lamivudine—hepatitis B	0.00233	0.00354	CcSEcCtD
Rasagiline—BCL2—IL2-mediated signaling events—IL2—hepatitis B	0.00232	0.00679	CbGpPWpGaD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NFKB1—hepatitis B	0.00231	0.00676	CbGpPWpGaD
Rasagiline—Malnutrition—Lamivudine—hepatitis B	0.00229	0.00349	CcSEcCtD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—PTEN—hepatitis B	0.00229	0.00669	CbGpPWpGaD
Rasagiline—Diarrhoea—Telbivudine—hepatitis B	0.00227	0.00346	CcSEcCtD
Rasagiline—Flatulence—Lamivudine—hepatitis B	0.00226	0.00344	CcSEcCtD
Rasagiline—Dysgeusia—Lamivudine—hepatitis B	0.00225	0.00341	CcSEcCtD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TNF—hepatitis B	0.00224	0.00655	CbGpPWpGaD
Rasagiline—Back pain—Lamivudine—hepatitis B	0.00222	0.00337	CcSEcCtD
Rasagiline—Muscle spasms—Lamivudine—hepatitis B	0.00221	0.00335	CcSEcCtD
Rasagiline—Dizziness—Telbivudine—hepatitis B	0.0022	0.00334	CcSEcCtD
Rasagiline—MAOB—Biological oxidations—GGT1—hepatitis B	0.00219	0.00641	CbGpPWpGaD
Rasagiline—Tremor—Lamivudine—hepatitis B	0.00215	0.00327	CcSEcCtD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—TGFB1—hepatitis B	0.00213	0.00624	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Lamivudine—hepatitis B	0.00213	0.00324	CcSEcCtD
Rasagiline—Anaemia—Lamivudine—hepatitis B	0.00212	0.00322	CcSEcCtD
Rasagiline—Vomiting—Telbivudine—hepatitis B	0.00211	0.00321	CcSEcCtD
Rasagiline—Rash—Telbivudine—hepatitis B	0.00209	0.00318	CcSEcCtD
Rasagiline—Dermatitis—Telbivudine—hepatitis B	0.00209	0.00318	CcSEcCtD
Rasagiline—Headache—Telbivudine—hepatitis B	0.00208	0.00316	CcSEcCtD
Rasagiline—Malaise—Lamivudine—hepatitis B	0.00207	0.00314	CcSEcCtD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—TNF—hepatitis B	0.00207	0.00605	CbGpPWpGaD
Rasagiline—Vertigo—Lamivudine—hepatitis B	0.00206	0.00313	CcSEcCtD
Rasagiline—Syncope—Lamivudine—hepatitis B	0.00206	0.00313	CcSEcCtD
Rasagiline—Leukopenia—Lamivudine—hepatitis B	0.00205	0.00312	CcSEcCtD
Rasagiline—Loss of consciousness—Lamivudine—hepatitis B	0.00202	0.00306	CcSEcCtD
Rasagiline—Cough—Lamivudine—hepatitis B	0.002	0.00304	CcSEcCtD
Rasagiline—Convulsion—Lamivudine—hepatitis B	0.00199	0.00302	CcSEcCtD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—hepatitis B	0.00198	0.00577	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—TP53—hepatitis B	0.00198	0.00577	CbGpPWpGaD
Rasagiline—Nausea—Telbivudine—hepatitis B	0.00197	0.003	CcSEcCtD
Rasagiline—BCL2—IL-3 Signaling Pathway—TGFB1—hepatitis B	0.00196	0.00572	CbGpPWpGaD
Rasagiline—Arthralgia—Lamivudine—hepatitis B	0.00195	0.00297	CcSEcCtD
Rasagiline—Chest pain—Lamivudine—hepatitis B	0.00195	0.00297	CcSEcCtD
Rasagiline—Anxiety—Lamivudine—hepatitis B	0.00195	0.00296	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.00194	0.00295	CcSEcCtD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CDKN1A—hepatitis B	0.00194	0.00566	CbGpPWpGaD
Rasagiline—Discomfort—Lamivudine—hepatitis B	0.00193	0.00293	CcSEcCtD
Rasagiline—Dry mouth—Lamivudine—hepatitis B	0.00191	0.0029	CcSEcCtD
Rasagiline—Confusional state—Lamivudine—hepatitis B	0.00189	0.00287	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN2A—hepatitis B	0.00188	0.0055	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CDKN2A—hepatitis B	0.00188	0.0055	CbGpPWpGaD
Rasagiline—Infection—Lamivudine—hepatitis B	0.00186	0.00283	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—FAS—hepatitis B	0.00186	0.00543	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—TNF—hepatitis B	0.00186	0.00543	CbGpPWpGaD
Rasagiline—Shock—Lamivudine—hepatitis B	0.00184	0.0028	CcSEcCtD
Rasagiline—Nervous system disorder—Lamivudine—hepatitis B	0.00184	0.00279	CcSEcCtD
Rasagiline—CYP1A2—Phase II conjugation—GGT2—hepatitis B	0.00184	0.00536	CbGpPWpGaD
Rasagiline—Skin disorder—Lamivudine—hepatitis B	0.00182	0.00276	CcSEcCtD
Rasagiline—Hyperhidrosis—Lamivudine—hepatitis B	0.00181	0.00275	CcSEcCtD
Rasagiline—Anorexia—Lamivudine—hepatitis B	0.00178	0.00271	CcSEcCtD
Rasagiline—BCL2—Apoptosis—FASLG—hepatitis B	0.00178	0.0052	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CD4—hepatitis B	0.00177	0.00518	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CDKN2A—hepatitis B	0.00177	0.00516	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—TP53—hepatitis B	0.00176	0.00513	CbGpPWpGaD
Rasagiline—Hypotension—Lamivudine—hepatitis B	0.00175	0.00266	CcSEcCtD
Rasagiline—BCL2—Apoptosis—FAS—hepatitis B	0.00171	0.00501	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.00171	0.00259	CcSEcCtD
Rasagiline—Insomnia—Lamivudine—hepatitis B	0.00169	0.00257	CcSEcCtD
Rasagiline—Paraesthesia—Lamivudine—hepatitis B	0.00168	0.00256	CcSEcCtD
Rasagiline—Dyspnoea—Lamivudine—hepatitis B	0.00167	0.00254	CcSEcCtD
Rasagiline—Somnolence—Lamivudine—hepatitis B	0.00166	0.00253	CcSEcCtD
Rasagiline—Dyspepsia—Lamivudine—hepatitis B	0.00165	0.00251	CcSEcCtD
Rasagiline—Decreased appetite—Lamivudine—hepatitis B	0.00163	0.00247	CcSEcCtD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—TNF—hepatitis B	0.00162	0.00473	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Lamivudine—hepatitis B	0.00162	0.00246	CcSEcCtD
Rasagiline—Constipation—Lamivudine—hepatitis B	0.0016	0.00243	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN2A—hepatitis B	0.00157	0.0046	CbGpPWpGaD
Rasagiline—Feeling abnormal—Lamivudine—hepatitis B	0.00154	0.00235	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN1A—hepatitis B	0.00154	0.0045	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IFNG—hepatitis B	0.00154	0.00449	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Lamivudine—hepatitis B	0.00153	0.00233	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN2A—hepatitis B	0.00153	0.00447	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—NFKB1—hepatitis B	0.00153	0.00446	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—IL2—hepatitis B	0.00152	0.00443	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A6—hepatitis B	0.00151	0.00441	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—FASLG—hepatitis B	0.0015	0.0044	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP2A6—hepatitis B	0.00149	0.00436	CbGpPWpGaD
Rasagiline—Urticaria—Lamivudine—hepatitis B	0.00149	0.00226	CcSEcCtD
Rasagiline—Body temperature increased—Lamivudine—hepatitis B	0.00148	0.00225	CcSEcCtD
Rasagiline—Abdominal pain—Lamivudine—hepatitis B	0.00148	0.00225	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—CTNNB1—hepatitis B	0.00146	0.00428	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—FAS—hepatitis B	0.00145	0.00424	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—NFKB1—hepatitis B	0.00143	0.00419	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—NFKB1—hepatitis B	0.00142	0.00415	CbGpPWpGaD
Rasagiline—Hypersensitivity—Lamivudine—hepatitis B	0.00138	0.0021	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—GGT1—hepatitis B	0.00136	0.00399	CbGpPWpGaD
Rasagiline—Asthenia—Lamivudine—hepatitis B	0.00134	0.00204	CcSEcCtD
Rasagiline—Pruritus—Lamivudine—hepatitis B	0.00132	0.00201	CcSEcCtD
Rasagiline—BCL2—Immune System—IFNAR2—hepatitis B	0.00132	0.00384	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN1A—hepatitis B	0.00129	0.00376	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—PTEN—hepatitis B	0.00128	0.00375	CbGpPWpGaD
Rasagiline—Diarrhoea—Lamivudine—hepatitis B	0.00128	0.00195	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CTNNB1—hepatitis B	0.00128	0.00374	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—IL6—hepatitis B	0.00127	0.00372	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN1A—hepatitis B	0.00125	0.00365	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PTEN—hepatitis B	0.00125	0.00364	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—NFKB1—hepatitis B	0.00124	0.00362	CbGpPWpGaD
Rasagiline—Dizziness—Lamivudine—hepatitis B	0.00124	0.00188	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—hepatitis B	0.00122	0.00358	CbGpPWpGaD
Rasagiline—Vomiting—Lamivudine—hepatitis B	0.00119	0.00181	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TNF—hepatitis B	0.00119	0.00347	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—TGFB1—hepatitis B	0.00118	0.00346	CbGpPWpGaD
Rasagiline—Rash—Lamivudine—hepatitis B	0.00118	0.00179	CcSEcCtD
Rasagiline—Dermatitis—Lamivudine—hepatitis B	0.00118	0.00179	CcSEcCtD
Rasagiline—Headache—Lamivudine—hepatitis B	0.00117	0.00178	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-DPA1—hepatitis B	0.00115	0.00336	CbGpPWpGaD
Rasagiline—Nausea—Lamivudine—hepatitis B	0.00111	0.00169	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—AKR1B1—hepatitis B	0.0011	0.00323	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD274—hepatitis B	0.00109	0.00318	CbGpPWpGaD
Rasagiline—BCL2—Immune System—UBE2L3—hepatitis B	0.00109	0.00318	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GGT2—hepatitis B	0.00107	0.00314	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TGFB1—hepatitis B	0.00106	0.00311	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—hepatitis B	0.00105	0.00306	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TGFB1—hepatitis B	0.00103	0.00302	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—CDKN1A—hepatitis B	0.00102	0.00299	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—PTEN—hepatitis B	0.00102	0.00298	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PDCD1—hepatitis B	0.000997	0.00291	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CTNNB1—hepatitis B	0.000985	0.00288	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—hepatitis B	0.000982	0.00287	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CTNNB1—hepatitis B	0.000965	0.00282	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—PTEN—hepatitis B	0.00096	0.00281	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—NFKB1—hepatitis B	0.000955	0.00279	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNGR1—hepatitis B	0.000927	0.00271	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—hepatitis B	0.000876	0.00256	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—TLR2—hepatitis B	0.000872	0.00255	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—GGT1—hepatitis B	0.000868	0.00254	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFNB1—hepatitis B	0.000865	0.00253	CbGpPWpGaD
Rasagiline—CYP1A2—Melatonin metabolism and effects—NFKB1—hepatitis B	0.000852	0.00249	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—hepatitis B	0.00085	0.00249	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFNA1—hepatitis B	0.000844	0.00247	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKR1B1—hepatitis B	0.000827	0.00242	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CTNNB1—hepatitis B	0.00082	0.0024	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CTNNB1—hepatitis B	0.000816	0.00239	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL6—hepatitis B	0.000802	0.00234	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PTEN—hepatitis B	0.000799	0.00233	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDKN1A—hepatitis B	0.000797	0.00233	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MX1—hepatitis B	0.000797	0.00233	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTEN—hepatitis B	0.000795	0.00232	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GGT2—hepatitis B	0.000793	0.00232	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—NFKB1—hepatitis B	0.000792	0.00231	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CD14—hepatitis B	0.000786	0.0023	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFNA2—hepatitis B	0.000786	0.0023	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—hepatitis B	0.000728	0.00213	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—hepatitis B	0.000708	0.00207	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—TP53—hepatitis B	0.000696	0.00203	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	0.000659	0.00193	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—hepatitis B	0.000655	0.00191	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP2A6—hepatitis B	0.00065	0.0019	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—hepatitis B	0.000642	0.00188	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—hepatitis B	0.000629	0.00184	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TNF—hepatitis B	0.000616	0.0018	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—hepatitis B	0.000593	0.00173	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—hepatitis B	0.000589	0.00172	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HSPA5—hepatitis B	0.000559	0.00163	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	0.000543	0.00159	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—TLR4—hepatitis B	0.000539	0.00157	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-DPB1—hepatitis B	0.000528	0.00154	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GGT1—hepatitis B	0.000508	0.00148	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TLR2—hepatitis B	0.000508	0.00148	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNB1—hepatitis B	0.000504	0.00147	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA1—hepatitis B	0.000492	0.00144	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—hepatitis B	0.000491	0.00143	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP2A6—hepatitis B	0.000481	0.0014	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—hepatitis B	0.000458	0.00134	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—hepatitis B	0.000458	0.00134	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD14—hepatitis B	0.000458	0.00134	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA2—hepatitis B	0.000458	0.00134	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GOT2—hepatitis B	0.000435	0.00127	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—hepatitis B	0.00043	0.00126	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL18—hepatitis B	0.000391	0.00114	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD40LG—hepatitis B	0.000389	0.00114	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD8A—hepatitis B	0.000385	0.00112	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CD4—hepatitis B	0.000379	0.00111	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GGT1—hepatitis B	0.000375	0.0011	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GOT1—hepatitis B	0.000375	0.0011	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-A—hepatitis B	0.000343	0.001	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CTNNB1—hepatitis B	0.000337	0.000985	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CDKN1A—hepatitis B	0.000329	0.000962	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PTEN—hepatitis B	0.000328	0.00096	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—NFKB1—hepatitis B	0.000327	0.000955	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TLR4—hepatitis B	0.000314	0.000917	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-DRB1—hepatitis B	0.000313	0.000916	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNG—hepatitis B	0.000229	0.000669	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD4—hepatitis B	0.000221	0.000646	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6—hepatitis B	0.000205	0.0006	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—hepatitis B	0.000203	0.000594	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALB—hepatitis B	0.0002	0.000583	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTNNB1—hepatitis B	0.000196	0.000574	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	0.000195	0.00057	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1A—hepatitis B	0.000192	0.00056	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKR1B1—hepatitis B	0.000191	0.00056	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—hepatitis B	0.000191	0.000559	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NFKB1—hepatitis B	0.00019	0.000556	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GGT2—hepatitis B	0.000184	0.000537	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—hepatitis B	0.000152	0.000445	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6—hepatitis B	0.00012	0.000349	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2A6—hepatitis B	0.000111	0.000325	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hepatitis B	0.000104	0.000303	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GOT2—hepatitis B	0.000101	0.000294	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GOT1—hepatitis B	8.68e-05	0.000254	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GGT1—hepatitis B	8.68e-05	0.000254	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	7.91e-05	0.000231	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALB—hepatitis B	4.62e-05	0.000135	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—hepatitis B	3.52e-05	0.000103	CbGpPWpGaD
